1. Kim JS. Stroke in Asia: a global disaster. Int J Stroke. 2014; 9:856–857.
2. Toyoda K, Koga M, Hayakawa M, Yamagami H. Acute reperfusion therapy and stroke care in Asia after successful endovascular trials. Stroke. 2015; 46:1474–1481.
3. Nam HS, Kim YD, Choi JK, Baik M, Kim BM, Kim DJ, et al. Outcome in Patients Treated with Intra-arterial thrombectomy: The optiMAL Blood Pressure control (OPTIMAL-BP) trial. Int J Stroke. 2022; 17:931–937.
4. Yoshimura S, Sakai N, Yamagami H, Uchida K, Beppu M, Toyoda K, et al. Endovascular therapy for acute stroke with a large ischemic region. N Engl J Med. 2022; 386:1303–1313.
5. Sakamoto Y, Nishiyama Y, Iwasaki YK, Daida H, Toyoda K, Kitagawa K, et al. Design and rationale of the STroke secondary prevention with catheter ABLation and EDoxaban clinical trial in patients with non-valvular atrial fibrillation: the STABLED study. J Cardiol. 2019; 74:539–542.
6. Jeong HG, Kim BJ, Kim T, Kang J, Kim JY, Kim J, et al. Classification of cardioembolic stroke based on a deep neural network using chest radiographs. EBioMedicine. 2021; 69:103466.
7. Song TJ, Baek IY, Woo HG, Kim YJ, Chang Y, Kim BJ, et al. Characteristics and factors for short-term functional outcome in stroke patients with atrial fibrillation, nationwide retrospective cohort study. Front Neurol. 2019; 10:1101.
8. Ihara M, Yamamoto Y, Hattori Y, Liu W, Kobayashi H, Ishiyama H, et al. Moyamoya disease: diagnosis and interventions. Lancet Neurol. 2022; 21:747–758.
9. Park YJ, Niizuma K, Mokin M, Dezawa M, Borlongan CV. Cell-based therapy for stroke: musing with Muse cells. Stroke. 2020; 51:2854–2862.
11. Venketasubramanian N, Anderson C, Ay H, Aybek S, Brinjikji W, de Freitas GR, et al. Stroke care during the COVID-19 pandemic: international expert panel review. Cerebrovasc Dis. 2021; 50:245–261.